RxDoctor Payments Data

Cassaundra Thompson

Family Medicine · Jacksonville, FLNPI 1124569215

Payments from drug & device makers

$1,047in general payments, 2019–2025

Across 38 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$221
  • AstraZeneca$160
  • AbbVie$154
  • Novo Nordisk$124
  • Medtronic$110
  • Biohaven Pharmaceutical Holding Company Ltd.$69
  • plus $210 from 7 others

What the payments were for

  • Food & beverage$1,047100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,047 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$25,807
Medicare patients
99
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$74,148
JanuviaSitagliptin Phosphate17$20,805
EliquisApixaban17$16,168
FarxigaDapagliflozin Propanediol11$15,843
JardianceEmpagliflozin12$14,217
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,411
Varenicline Tartrate13$3,447
Atorvastatin Calcium218$2,389
SynthroidLevothyroxine Sodium20$2,075
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,442
Albuterol Sulfate HfaAlbuterol Sulfate76$1,353
Amlodipine Besylate159$1,199
Losartan Potassium132$1,097
Gabapentin59$1,034
Lisinopril132$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$124$74,14860 claims
AstraZenecaFarxiga$160$15,84311 claims
Boehringer IngelheimJardiance$63$14,21712 claims
GSKTrelegy Ellipta$221$9,41113 claims
AbbVieSynthroid$154$2,07520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →